Literature DB >> 33123732

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.

Quinn T Ostrom1,2, Nirav Patil1,3,4,5, Gino Cioffi1,3,4, Kristin Waite1,3,4, Carol Kruchko1, Jill S Barnholtz-Sloan1,3,6,4,5.   

Abstract

The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors (malignant and non-malignant) and supersedes all previous CBTRUS reports in terms of completeness and accuracy. All rates (incidence and mortality) are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 23.79 (Malignant AAAIR=7.08, non-Malignant AAAIR=16.71). This rate was higher in females compared to males (26.31 versus 21.09), Blacks compared to Whites (23.88 versus 23.83), and non-Hispanics compared to Hispanics (24.23 versus 21.48). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.5% of all tumors), and the most common non-malignant tumor was meningioma (38.3% of all tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.14. An estimated 83,830 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US in 2020 (24,970 malignant and 58,860 non-malignant). There were 81,246 deaths attributed to malignant brain and other CNS tumors between 2013 and 2017. This represents an average annual mortality rate of 4.42. The 5-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 23.5% and for a non-malignant brain and other CNS tumor was 82.4%.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2020        PMID: 33123732      PMCID: PMC7596247          DOI: 10.1093/neuonc/noaa200

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  78 in total

Review 1.  Review of molecular classification and treatment implications of pediatric brain tumors.

Authors:  Ana S Guerreiro Stucklin; Vijay Ramaswamy; Craig Daniels; Michael D Taylor
Journal:  Curr Opin Pediatr       Date:  2018-02       Impact factor: 2.856

2.  International Classification of Childhood Cancer, third edition.

Authors:  Eva Steliarova-Foucher; Charles Stiller; Brigitte Lacour; Peter Kaatsch
Journal:  Cancer       Date:  2005-04-01       Impact factor: 6.860

3.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

4.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Authors:  Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape
Journal:  Cancer Cell       Date:  2010-04-15       Impact factor: 31.743

Review 5.  Chemoradiotherapy in malignant glioma: standard of care and future directions.

Authors:  Roger Stupp; Monika E Hegi; Mark R Gilbert; Arnab Chakravarti
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

Review 6.  Epidemiology and etiology of meningioma.

Authors:  Joseph Wiemels; Margaret Wrensch; Elizabeth B Claus
Journal:  J Neurooncol       Date:  2010-09-07       Impact factor: 4.130

7.  Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014.

Authors:  Quinn T Ostrom; David J Cote; Mustafa Ascha; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

Review 8.  Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review.

Authors:  Melissa Z Braganza; Cari M Kitahara; Amy Berrington de González; Peter D Inskip; Kimberly J Johnson; Preetha Rajaraman
Journal:  Neuro Oncol       Date:  2012-09-05       Impact factor: 12.300

9.  Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients.

Authors:  Beatrice Malmer; Roger Henriksson; Henrik Grönberg
Journal:  Int J Cancer       Date:  2003-08-20       Impact factor: 7.396

10.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.

Authors:  Marcel Kool; Andrey Korshunov; Marc Remke; David T W Jones; Maria Schlanstein; Paul A Northcott; Yoon-Jae Cho; Jan Koster; Antoinette Schouten-van Meeteren; Dannis van Vuurden; Steven C Clifford; Torsten Pietsch; Andre O von Bueren; Stefan Rutkowski; Martin McCabe; V Peter Collins; Magnus L Bäcklund; Christine Haberler; Franck Bourdeaut; Olivier Delattre; Francois Doz; David W Ellison; Richard J Gilbertson; Scott L Pomeroy; Michael D Taylor; Peter Lichter; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2012-02-23       Impact factor: 17.088

View more
  385 in total

Review 1.  Major Features of the 2021 WHO Classification of CNS Tumors.

Authors:  Heather L Smith; Nitin Wadhwani; Craig Horbinski
Journal:  Neurotherapeutics       Date:  2022-05-16       Impact factor: 7.620

Review 2.  The implications of IDH mutations for cancer development and therapy.

Authors:  Christopher J Pirozzi; Hai Yan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

3.  Commentary: The Ki-67 Proliferation Index as a Marker of Time to Recurrence in Intracranial Meningioma.

Authors:  Antonio Dono; Ankush Chandra; Leomar Y Ballester; Yoshua Esquenazi
Journal:  Neurosurgery       Date:  2021-06-15       Impact factor: 4.654

4.  Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US.

Authors:  Quinn T Ostrom; Halle L Krebs; Nirav Patil; Gino Cioffi; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2021-03-23       Impact factor: 4.130

5.  Height in adolescence as a risk factor for glioma subtypes: a nationwide retrospective cohort study of 2.2 million subjects.

Authors:  Roi Tschernichovsky; Lior H Katz; Estela Derazne; Matan Ben-Zion Berliner; Maya Simchoni; Hagai Levine; Lital Keinan-Boker; Alexandra Benouaich-Amiel; Andrew A Kanner; Yosef Laviv; Asaf Honig; Elizabeth Dudnik; Tali Siegal; Jacob Mandel; Gilad Twig; Shlomit Yust-Katz
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

Review 6.  Leveraging the replication-competent avian-like sarcoma virus/tumor virus receptor-A system for modeling human gliomas.

Authors:  Pranjali P Kanvinde; Adarsha P Malla; Nina P Connolly; Frank Szulzewsky; Pavlos Anastasiadis; Heather M Ames; Anthony J Kim; Jeffrey A Winkles; Eric C Holland; Graeme F Woodworth
Journal:  Glia       Date:  2021-02-27       Impact factor: 7.452

7.  Elevated fibroblast growth factor-inducible 14 expression transforms proneural-like gliomas into more aggressive and lethal brain cancer.

Authors:  Nina P Connolly; Rebeca Galisteo; Su Xu; Eli E Bar; Sen Peng; Nhan L Tran; Heather M Ames; Anthony J Kim; Graeme F Woodworth; Jeffrey A Winkles
Journal:  Glia       Date:  2021-05-15       Impact factor: 7.452

8.  MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma.

Authors:  Zhongyuan Bao; Lingyang Hua; Yangfan Ye; Daijun Wang; Chong Li; Qing Xie; Hiroaki Wakimoto; Ye Gong; Jing Ji
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 12.300

9.  Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.

Authors:  Mary Jane Lim-Fat; Kun Wei Song; J Bryan Iorgulescu; Brian M Andersen; Deborah A Forst; Justin T Jordan; Elizabeth R Gerstner; David A Reardon; Patrick Y Wen; Isabel Arrillaga-Romany
Journal:  J Neurooncol       Date:  2021-03-01       Impact factor: 4.130

Review 10.  Genotoxic therapy and resistance mechanism in gliomas.

Authors:  Fengchao Lang; Yang Liu; Fu-Ju Chou; Chunzhang Yang
Journal:  Pharmacol Ther       Date:  2021-06-23       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.